Jefferies initiated coverage on Azenta with a new price target
$AZTA
Industrial Machinery/Components
Technology
Jefferies initiated coverage of Azenta with a rating of Hold and set a new price target of $64.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/18/2024 | $50.00 → $60.00 | Equal-Weight → Overweight | Stephens |
| 4/4/2024 | $64.00 | Hold | Jefferies |
| 2/1/2024 | $61.00 → $79.00 | Buy | B. Riley Securities |
| 7/19/2023 | Mkt Perform | Raymond James | |
| 5/10/2023 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 2/9/2023 | $65.00 → $60.00 | Overweight → Equal-Weight | Stephens |
| 1/3/2023 | $60.00 → $62.00 | Outperform → In-line | Evercore ISI |
| 3/31/2022 | $106.00 | Buy | B. Riley Securities |
NEW YORK, Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE:ENV) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 25. Bain Capital is acquiring Envestnet in a deal expected to be completed soon, pending final closing conditions. Azenta's market capitalization is no longer representative of the mid-cap market space.Concentra Group Holdings Inc. (NYSE:CON) will replace Myers Industries Inc. (NYSE:MYE) in the S&P SmallCap 600 effective prior to the openin
William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced the appointment of three new independent directors to its Board. William Cornog, former head of KKR Capstone, the portfolio operations team of KKR & Co., and Alan Malus, former Corporate Executive Vice President of Thermo Fisher, join as part of Azenta's ongoing i
Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition. Mr. Marotta has two decades of experience leading global companies in life sciences, medical devices, and diagnostics, and is joining Azenta from Patient Square Capital, a leading healthcare investment firm, where he serves as Executive in Residence. P
4 - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
BURLINGTON, Mass., Feb. 5, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the first quarter ended December 31, 2024. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the fourth fiscal quarter of 2024 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data December 31, September 30, December 31, Change 2024 2024 2023 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 148 $ 151 $ 142 (2) % 4 % Organic growth 4 % Sample Management Solutions $ 81 $ 85 $ 79 (4) % 3 % Multiomics $ 66 $ 66 $ 63 0 % 6 % Diluted EPS Continui
BURLINGTON, Mass., Jan. 30, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ:TRDA) and a recognized leader in the biotechnology and pharmaceutical industries, has been elected to its Board of Directors at its Annual Meeting of Stockholders held earlier today. Mr. Doshi was nominated for election by the Board, together with nine returning directors, in December 2024. "Mr. Doshi is an extraordinary leader who brings significant experience in the biotechnology and pharmaceutical industries," said John Marotta, President and CEO of Azenta. "His experience in strategy, operational and commercial growth, and
BURLINGTON, Mass., Jan. 27, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal first quarter 2025 earnings which ended on December 31, 2024, on Wednesday February 5, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, February 5, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on February 6, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide
10-Q - Azenta, Inc. (0000933974) (Filer)
8-K - Azenta, Inc. (0000933974) (Filer)
8-K - Azenta, Inc. (0000933974) (Filer)
SC 13G/A - Azenta, Inc. (0000933974) (Subject)
SC 13D/A - Azenta, Inc. (0000933974) (Subject)
SC 13G - Azenta, Inc. (0000933974) (Subject)
4 - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
Stephens upgraded Azenta from Equal-Weight to Overweight and set a new price target of $60.00 from $50.00 previously
Jefferies initiated coverage of Azenta with a rating of Hold and set a new price target of $64.00
B. Riley Securities reiterated coverage of Azenta with a rating of Buy and set a new price target of $79.00 from $61.00 previously
BURLINGTON, Mass., Feb. 5, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the first quarter ended December 31, 2024. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the fourth fiscal quarter of 2024 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data December 31, September 30, December 31, Change 2024 2024 2023 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 148 $ 151 $ 142 (2) % 4 % Organic growth 4 % Sample Management Solutions $ 81 $ 85 $ 79 (4) % 3 % Multiomics $ 66 $ 66 $ 63 0 % 6 % Diluted EPS Continui
BURLINGTON, Mass., Jan. 27, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal first quarter 2025 earnings which ended on December 31, 2024, on Wednesday February 5, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, February 5, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on February 6, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide
FY'24 revenue growth of 4%, reported and organic, in combined Sample Management Solutions and MultiomicsFY'25 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis pointsPursuing a sale of B Medical Systems to simplify portfolio and drive revenue growth and profitabilityAnnounces appointment of Lawrence Y. Lin as Chief Financial Officer; Herman Cueto to remain as advisor to ensure smooth transitionBURLINGTON, Mass., Nov. 12, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2024. Fiscal Year 2024 Highlights: Q4'24 revenue growth o